Evaluation of the first commercial hepcidin ELISA for the differential diagnosis of anemia of chronic disease and iron deficiency anemia in hospitalized geriatric patients

Abstract Introduction: Anemia is a frequent problem in hospitalized geriatric patients, and the anemia of chronic disease (ACD) and iron deficiency anemia (IDA) are the 2 most prevalent causes. The aim of the study was to assess the possible role of serum hepcidin in the differential diagnosis between ACD and IDA.
Methods: We investigated serum hepcidin, iron status, anemia, and C-reactive protein in 39 consecutive geriatric patients with ACD and IDA. Serum hepcidin levels were determined using a commercial ELISA kit (DRG Instruments, Marburg, Germany). We also measured hepcidin in 26 healthy controls.
Results: The serum hepcidin levels were not significantly higher in the 28 patients with ACD as compared to the 11 patients with IDA.
Conclusions: The serum hepcidin levels measured using the commercial ELISA kit (DRG) do not appear to increase in older patients with ACD. It should be noted that an assay-specific problem could explain our results.

DRG product(s) used in the study above

You can view the product details and buy it now

Hepcidin -25 (bioactive) HS Geerts I., Vermeersch P., Joosten E.,

Author Information

ISRN Hematol. 2012;2012:567491

Link: https://www.ncbi.nlm.nih.gov/pubmed/22461996

by DRG International | May 2, 2018